176 related articles for article (PubMed ID: 22759200)
1. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.
Alloway RR; Sadaka B; Trofe-Clark J; Wiland A; Bloom RD
Am J Transplant; 2012 Oct; 12(10):2825-31. PubMed ID: 22759200
[TBL] [Abstract][Full Text] [Related]
2. A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients.
Bloom RD; Trofe-Clark J; Wiland A; Alloway RR
Clin Transplant; 2013; 27(6):E685-93. PubMed ID: 24118450
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients.
Min SI; Ha J; Kim YS; Ahn SH; Park T; Park DD; Kim SM; Min SK; Hong H; Ahn C; Kim SJ
Nephrol Dial Transplant; 2013 Dec; 28(12):3110-9. PubMed ID: 24084327
[TBL] [Abstract][Full Text] [Related]
6. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
[TBL] [Abstract][Full Text] [Related]
8. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen.
Florman S; Alloway R; Kalayoglu M; Lake K; Bak T; Klein A; Klintmalm G; Busque S; Brandenhagen D; Lake J; Wisemandle K; Fitzsimmons W; First MR
Transplant Proc; 2005 Mar; 37(2):1211-3. PubMed ID: 15848672
[TBL] [Abstract][Full Text] [Related]
9. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
[TBL] [Abstract][Full Text] [Related]
10. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed.
Robertsen I; Åsberg A; Ingerø AO; Vethe NT; Bremer S; Bergan S; Midtvedt K
Transplantation; 2015 Mar; 99(3):528-32. PubMed ID: 25148382
[TBL] [Abstract][Full Text] [Related]
11. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
[TBL] [Abstract][Full Text] [Related]
13. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function.
Momper JD; Ridenour TA; Schonder KS; Shapiro R; Humar A; Venkataramanan R
Am J Transplant; 2011 Sep; 11(9):1861-7. PubMed ID: 21714845
[TBL] [Abstract][Full Text] [Related]
14. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
15. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
Kuypers DR; Vanrenterghem Y
Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
[TBL] [Abstract][Full Text] [Related]
16. STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany.
Lehner LJ; Kalb K; Weigand K; Pein U; Schenker P; Seeger W; Roehle R; Dienes K; Halleck F; Budde K
Curr Rev Clin Exp Pharmacol; 2021; 16(4):357-368. PubMed ID: 33588739
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
18. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.
Velickovic-Radovanovic R; Mikov M; Catic-Djordjevic A; Stefanovic N; Mitic B; Paunovic G; Cvetkovic T
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):95-102. PubMed ID: 24596067
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.
Jones TE; Morris RG
Clin Pharmacokinet; 2002; 41(5):381-8. PubMed ID: 12036394
[TBL] [Abstract][Full Text] [Related]
20. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
